Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using 131 I-whole body scans to identify metastases of differentiated thyroid cancer

Liepe, Knut

doi:10.1016/j.ijsu.2015.02.016

Cited by 4 publications

(1 citation statement)

References 30 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present results showed that dTAT NP-NIS inhibits cell growth and induces cellular apoptosis in TPC-1 cells. At present, a comprehensive therapeutic method for PTC involves surgery assisted by endocrinotherapy and radioactive I-131 treatment (22). Located on the epithelial cell membrane, NIS is a type of glycoprotein, whose genes are on the short arm of chromosome 19 (23).…”

Section: Discussionmentioning

confidence: 99%

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Fan

Liang

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present study was to clarify whether the cell penetrating peptide of sodium-iodide symporter (NIS) has an effect on the I-131 radiotherapy of thyroid cancer. Firstly, we combined the HIV-1 TAT peptide (a cell penetrating peptide, dTAT) and established a nanoparticle vector (dTAT NP) to study the delivery efficiency of this cell-penetrating strategy for tumor-targeted gene delivery. dTAT NP was transfected into cultured TPC-1 cells as a model to study the effects of I-131 radiotherapy on thyroid cancer. Reverse transcription-quantitative polymerase chain reaction and western blotting results showed that the mRNA and protein expression levels of NIS in the transfected TPC-1 cells were substantially higher than in the negative control cells. MTT and flow cytometric analyses demonstrated that the cell growth and apoptosis rates of the TPC-1 cells were significantly inhibited and activated, respectively, by treatment with dTAT NP. The results of DAPI staining showed that treatment with dTAT NP visibly increased the nuclear apoptosis rate of the TPC-1 cells. The effect of dTAT NP on TPC-1 cells was associated with the promotion of caspase-3 and downregulation of the PI3K/Akt signaling pathway. In summary, the present data provide a pre-clinical proof-of-concept for a novel gene delivery system that efficiently delivers NIS to the targeted cancer cells and presents a satisfactory efficacy. This approach may offer an effective strategy for improving thyroid cancer gene therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Fan

Liang

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024

Kim,

Bang,

Kang

et al. 2024

Int J Thyroidol

View full text Add to dashboard Cite

Radio-Iodide Treatment: From Molecular Aspects to the Clinical View

Vieja

Riesco‐Eizaguirre

2021

Cancers

View full text Add to dashboard Cite

Thyroid radio-iodide therapy (RAI) is one of the oldest known and used targeted therapies. In thyroid cancer, it has been used for more than eight decades and is still being used to improve thyroid tumor treatment to eliminate remnants after thyroid surgery, and tumor metastases. Knowledge at the molecular level of the genes/proteins involved in the process has led to improvements in therapy, both from the point of view of when, how much, and how to use the therapy according to tumor type. The effectiveness of this therapy has spread into other types of targeted therapies, and this has made sodium/iodide symporter (NIS) one of the favorite theragnostic tools. Here we focus on describing the molecular mechanisms involved in radio-iodide therapy and how the alteration of these mechanisms in thyroid tumor progression affects the diagnosis and results of therapy in the clinic. We analyze basic questions when facing treatment, such as: (1) how the incorporation of radioiodine in normal, tumor, and metastatic thyroid cells occurs and how it is regulated; (2) the pros and cons of thyroid hormonal deprivation vs. recombinant human Thyroid Stimulating Hormone (rhTSH) in radioiodine residence time, treatment efficacy, thyroglobulin levels and organification, and its influence on diagnostic imaging tests and metastasis treatment; and (3) the effect of stunning and the possible causes. We discuss the possible incorporation of massive sequencing data into clinical practice, and we conclude with a socioeconomical and clinical vision of the above aspects.

show abstract

Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using 131 I-whole body scans to identify metastases of differentiated thyroid cancer

Abstract: In contrast to previously published data, this study couldn't found any differences in the sensitivity of rhTSH or THW for the preparation of DTC patients undergoing (131)I imaging.

Cited by 4 publications

References 30 publications

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024

Radio-Iodide Treatment: From Molecular Aspects to the Clinical View

Contact Info

Product

Resources

About